CTNI-23. SINGLE CELL TRANSCRIPTOMICS, PHARMACOKINETICS, AND PHARMACODYNAMICS OF COMBINED CDK4/6 AND MTOR INHIBITION IN A PHASE 0 TRIAL OF RECURRENT HIGH-GRADE GLIOMA
Johnson K, Tien A, Jiang J, McNamara J, Chang Y, Montgomery C, DeSantis A, Elena L, Fujita Y, Kim S, Tovmasyan A, Li J, Mehta S, Verhaak R, Sanai N. CTNI-23. SINGLE CELL TRANSCRIPTOMICS, PHARMACOKINETICS, AND PHARMACODYNAMICS OF COMBINED CDK4/6 AND MTOR INHIBITION IN A PHASE 0 TRIAL OF RECURRENT HIGH-GRADE GLIOMA. Neuro-Oncology 2023, 25: v78-v79. PMCID: PMC10639373, DOI: 10.1093/neuonc/noad179.0305.Peer-Reviewed Original ResearchHigh-grade gliomasRecurrent high-grade gliomaPhase 0 trialsStandard therapyPharmacodynamic effectsSurgical specimensMTOR inhibitionAdult high-grade gliomasCDKN2A/B deletionsDose-escalation cohortsIDH wild-type tumorsPharmacokinetics/pharmacodynamicsUnbound drug concentrationsGlioma cell linesRibociclib treatmentCell cycle inhibitionPIK3CA mutationsPreoperative MRIGlioma patientsRibociclibEverolimus concentrationsUnbound concentrationsPatientsSurgical tissuesB deletion